Insider · CIK 0001608936

Chacko Jacob

Reports to the SEC for 4 companies · EMERYVILLE, CA

sec.gov

Transactions

Companies

Filings

CIK

0001608936

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2026-01-02	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+675K sh	—	—	675,000
2026-01-02	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitA Award	Director, PRESIDENT AND CEO	AAward	+113K sh	—	—	112,500
2025-12-16	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−33.4K sh	$9.06	−$302K	581,711
2025-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−33.3K sh	—	—	66,667
2025-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−22K sh	—	—	0
2025-12-15	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	+83.7K sh	—	—	615,085
2025-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−28.3K sh	—	—	28,334
2025-10-06	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−37.5K sh	$12.32	−$462K	531,419
2025-10-01	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−53K sh	$12.05	−$639K	568,880
2025-09-30	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−34.5K sh	$12.01	−$415K	621,881
2025-09-22	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−125K sh	$10.80	−$1.35M	656,419
2025-06-17	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2025-01-02	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+600K sh	—	—	600,000
2025-01-02	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitA Award	Director, PRESIDENT AND CEO	AAward	+100K sh	—	—	100,000
2024-12-16	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−24.7K sh	$8.28	−$204K	778,648
2024-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−28.3K sh	—	—	56,667
2024-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−22K sh	—	—	22,000
2024-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−16.7K sh	—	—	0
2024-12-15	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	+67K sh	—	—	803,308
2024-05-21	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right To Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2024-03-06	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−40K sh	$16.21	−$648K	728,544
2024-02-07	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−26K sh	$12.29	−$320K	768,544
2024-02-06	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−14K sh	$12.12	−$169K	794,586
2024-01-02	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitA Award	Director, PRESIDENT AND CEO	AAward	+85K sh	—	—	85,000
2024-01-02	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+510K sh	—	—	510,000
2023-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−22K sh	—	—	44,000
2023-12-15	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	+38.7K sh	—	—	823,083
2023-12-15	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−14.5K sh	$8.58	−$125K	808,544
2023-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−16.7K sh	—	—	16,667
2023-07-11	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−5,156 sh	$8.01	−$41.3K	780,652
2023-07-10	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−10.5K sh	$8.01	−$84.2K	785,808
2023-07-05	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−4,336 sh	$8.01	−$34.7K	796,316
2023-06-26	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−20K sh	$8.03	−$161K	800,652
2023-05-23	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.5K sh	—	—	22,500
2023-04-21	FDMT4D Molecular Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−5,000 sh	—	—	32,500
2023-04-21	FDMT4D Molecular Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+5,000 sh	$9.41	+$47.1K	5,000
2023-04-21	FDMT4D Molecular Therapeutics, Inc.S Sale	Director	SSale	−5,000 sh	$20.05	−$100K	0
2023-02-01	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitA Award	Director, PRESIDENT AND CEO	AAward	+66K sh	—	—	66,000
2023-02-01	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+400K sh	—	—	400,000
2022-12-15	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−5,764 sh	$3.25	−$18.7K	817,025
2022-12-15	ORICOric Pharmaceuticals, Inc.S Sale	Director, PRESIDENT AND CEO	SSale	−6,137 sh	$3.07	−$18.9K	816,652
2022-12-15	ORICOric Pharmaceuticals, Inc. · Restricted Stock UnitM Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−16.7K sh	—	—	33,334
2022-12-15	ORICOric Pharmaceuticals, Inc.M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	+16.7K sh	—	—	822,789
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, PRESIDENT AND CEO	DDisposition to Issuer	−300K sh	—	—	0
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, PRESIDENT AND CEO	DDisposition to Issuer	−438K sh	—	—	0
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+280K sh	—	—	280,000
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)D Disposition to Issuer	Director, PRESIDENT AND CEO	DDisposition to Issuer	−280K sh	—	—	0
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+438K sh	—	—	437,500
2022-07-20	ORICOric Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director, PRESIDENT AND CEO	AAward	+300K sh	—	—	300,000

Recent filings

Accepted (ET)
Jun 184
Chacko Jacob0001193125-26-276138
SEC(opens sec.gov)
Jan 64
Chacko Jacob0001608936-26-000002
SEC(opens sec.gov)
Dec 174
Chacko Jacob0001608936-25-000014
SEC(opens sec.gov)
Oct 84
Chacko Jacob0001608936-25-000010
SEC(opens sec.gov)
Oct 24
Chacko Jacob0001608936-25-000008
SEC(opens sec.gov)
Sep 244
Chacko Jacob0001608936-25-000006
SEC(opens sec.gov)
Jun 204
Chacko Jacob0000950170-25-088497
SEC(opens sec.gov)
Jan 34
Chacko Jacob0001415889-25-000600
SEC(opens sec.gov)
Dec 174
Chacko Jacob0001415889-24-029631
SEC(opens sec.gov)

Companies

Address

C/O 4D MOLECULAR THERAPEUTICS, INC. 5858 HORTON STREET #455

EMERYVILLE, CA, 94608